Pall Life Sciences - - BioPharm International

ADVERTISEMENT

Pall Life Sciences

BioPharm International
Volume 18, Issue 12

Company Description



Pall is a leading global provider of filtration, purification, and separation technologies to the diverse and rapidly expanding life sciences market. Its products are used from the earliest stages of discovery and development of new drugs, through production and delivery of therapies for the prevention, diagnosis, and treatment of disease.

In the laboratory, Pall products help facilitate the drug discovery and development process to get innovative drugs to the market faster. In biopharmaceuticals, Pall products are applicable to laboratory- and pilot-scale development, aseptic processing, biologicals, bioprocessing, fermentation and downstream processing. In medical and transfusion medicine, Pall is a market leader in blood filtration systems to improve the quality and safety of the world's blood supply, and in medical filters that enhance the safety of cardiac surgery, drug delivery, intravenous feeding and accuracy of diagnostic tests.

Technical Services

Pall offers process development and process validation services together with pre-inspection reviews, as well as troubleshooting consultancy, training, contamination analysis and other technical assistance. Additional services are protein expression monitoring and multi-step chromatography purification development, target and impurity tracking and host cell protein assay development, purification optimization, and custom affinity sorbents.

Corporate Facilities

Pall maintains manufacturing facilities certified to ISO9001 in the United States, Puerto Rico, England, Ireland, France, Germany, Japan, India, and China.

Major Products



Pall Life Sciences provides membrane and membrane devices to optimize detection and sample preparation in basic drug research, clinical diagnostics, combinatorial chemistry and high throughput screening, as well as in the growing genomics and proteomics markets.

In pharmaceutical and bioprocess manufacturing, Pall offers full capability in chromatography and filtration. Pall's direct and tangential flow filtration technologies are used for biomass removal, clarification, particulate and bioburden reduction, prefiltration, sterile filtration of liquids and gases, mycoplasma, prion and virus clearance, endotoxin and DNA removal, and biomolecule purification and concentration. Products range from small laboratory- scale devices to large automated systems and filter test instruments. Pall's chromatography range includes membrane chromatography products already used on licensed products in the US and Europe, chromatography columns ranging from small pilot to fully engineered state-of-the-art columns, with fully automated axial compression packing up to 2.3 meters, packing and control systems, and full range of BioSepra media for ion exchange, affinity, hydroxy-apatite, hydrophobic charge induction, and size exclusion chromatography.



Pall's Scientific and Laboratory Services, and Validation Laboratory groups have been a cornerstone of support to its customers for more than 30 years. We employ more than 400 scientists, engineers and technicians in the Americas, Europe, Australia, and Asia.

Info #30

PALL LIFE SCIENCES
Division of Pall Corporation (PLL)

CORPORATE HEADQUARTERS USA
Pall Life Sciences 2200 Northern Blvd. East Hills,NY 11548

TOLL FREE:
800.717.7255

TELEPHONE:
516.484.5400

FAX:
516.801.9548

PALL EUROPE
Europa House Havant Street Portsmouth PO1 3PD UK

TELEPHONE:
+44(0).2392.303303

FAX:
+44(0).2392.302510

EMAIL:

WEB ADDRESS:
http://www.pall.com/

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Despite AbbVie Snub, Shire Says it Will Double Sales by 2020
October 24, 2014
Novartis Reports Positive Results for Secukinumab in Ankylosing Spondylitis Trials
October 23, 2014
Pall ForteBio Releases Bioprocessing Contamination Detection Kit
October 22, 2014
FDA Panel Unanimously Backs Secukinumab for the Treatment of Psoriasis
October 22, 2014
Roche to Expand and Improve its Basel Site
October 22, 2014
Author Guidelines
Source: BioPharm International,
Click here